GMP IPO Watch
Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO details, live grey market premium (GMP), dates, price band, lot size, subscription & review.
Symbiotec Pharmalab IPO Details
Key facts at a glance| IPO Open Date | 23 August 2026 | IPO Close Date | 26 August 2026 |
|---|---|---|---|
| Basis of Allotment | 27 August 2026 | Listing Date | 31 August 2026 |
| Price Band | ₹938 - ₹988 per share | Face Value | ₹10 per share |
| Market Lot Size | 15 Shares | Min Investment (Retail) | ₹14,820 |
| Total Issue Size | ₹2,180 Cr | Issue Type | Book Built Issue IPO |
| Fresh Issue | — | Offer for Sale (OFS) | — |
| Listing At | NSE, BSE | Issue Category | Mainboard Issue |
| Registrar | TBA | ||
Symbiotec Pharmalab IPO Timetable (Tentative Dates)
| Event | Tentative Date | Status |
|---|---|---|
| IPO Open Date | 23 August 2026 | Confirmed |
| IPO Close Date | 26 August 2026 | Confirmed |
| Basis of Allotment | 27 August 2026 | Tentative |
| Initiation of Refunds | TBA | Tentative |
| Credit of Shares to Demat | TBA | Tentative |
| IPO Listing Date | 31 August 2026 | Tentative |
| Cut-off time for UPI Mandate Confirmation | 5:00 PM on Closing Day | Deadline |
* Note: Timelines are tentative and subject to regulatory confirmation. UPI mandate approvals must be completed by 5:00 PM on the IPO closing day.
Symbiotec Pharmalab IPO Lot Size & Investment Details
Application limits for Retail and HNI investors| Application Category | Lots | Shares | Amount (at Cut-off) |
|---|---|---|---|
| Retail (Min) | 1 Lot | 15 Shares | ₹14,820 |
| Retail (Max) | 13 Lots | 195 Shares | ₹1,92,660 |
| S-HNI (Min) | 14 Lots | 210 Shares | ₹2,07,480 |
| S-HNI (Max) | 67 Lots | 1,005 Shares | ₹9,92,940 |
| B-HNI (Min) | 68 Lots | 1,020 Shares | ₹10,07,760 |
Symbiotec Pharmalab IPO Live GMP & Movement History
Daily unofficial grey market trends₹185 +18.7%
| Date | IPO GMP (₹) | Estimated Listing Price | Estimated Listing Gain (%) |
|---|---|---|---|
| 1 Sept 2026 | ₹185 | ₹1173.00 | +18.72% |
| 31 Aug 2026 | ₹260 | ₹1248.00 | +26.32% |
| 28 Aug 2026 | ₹275 | ₹1263.00 | +27.83% |
| 27 Aug 2026 | ₹285 | ₹1273.00 | +28.85% |
| 26 Aug 2026 | ₹352 | ₹1340.00 | +35.63% |
| 25 Aug 2026 | ₹340 | ₹1328.00 | +34.41% |
| 24 Aug 2026 | ₹409 | ₹1397.00 | +41.40% |
| 22 Aug 2026 | ₹345 | ₹1333.00 | +34.92% |
| 21 Aug 2026 | ₹320 | ₹1308.00 | +32.39% |
| 20 Aug 2026 | ₹200 | ₹1188.00 | +20.24% |
Symbiotec Pharmalab IPO Subscription Status
Demand breakdown by investor categoryAbout Symbiotec Pharmalab
Symbiotec Pharmalab Limited is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its API portfolio primarily focuses on steroidal products, while its CDMO business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house API capabilities to support these offerings. Revenue is generated through the sale of APIs, CDMO services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets while expanding into new therapeutic and fermentation-based product categories.
Key Strengths
- Operates an integrated business across APIs, CDMO services and complex injectables.
- Has one of India’s largest industrial-scale fermentation capacities with 700 KL capacity.
- Backward integration reduces dependence on external sources for key intermediates.
- Develops differentiated double-chamber injectable products using in-house API capabilities.
- Long-term manufacturing agreements and strategic partnerships support future business growth.
Key Risks
- Almost all revenue comes from API products, making the business dependent on API demand.
- A large share of revenue comes from a few key customers, and losing them could hurt the business.
- The company depends on key suppliers for raw materials, and supply disruptions could affect operations.
- The company faces intense competition in both the API and CDMO businesses.
- Failure to meet repayment obligations or loan covenants could adversely affect the business and finances.
Symbiotec Pharmalab IPO Reservation & Share Quotas
The Symbiotec Pharmalab IPO reservation is divided among Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), Retail Individual Investors and the anchor investor portion, where applicable.
As per the available category-wise allocation, 50% of the issue is allocated to Qualified Institutional Buyers excluding the anchor investor portion. 15% is allocated to Non-Institutional Investors, while 35% is reserved for Retail Individual Investors.
| Investor Category | Shares Offered | Shares (%) |
|---|---|---|
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Symbiotec Pharmalab IPO Anchor Investors
The Symbiotec Pharmalab IPO anchor bidding is scheduled for August 21, 2026, ahead of the public issue opening on August 24, 2026. The final anchor investor allocation, including the number of shares allotted and total anchor investment amount, is currently awaited.
The exact lock-in expiry dates for the anchor investor allocation will be updated once the final anchor allotment details and applicable IPO disclosures are available.
| Particular | Details |
|---|---|
| Anchor Bidding Date | August 21, 2026 |
| Anchor Investors List | |
| Shares Offered | – Shares |
| Anchor Size | – Cr. |
| Lock-in Period End Date – 50% Shares (30 Days) | 2026 |
| Lock-in Period End Date – Remaining 50% Shares (90 Days) | 2026 |
Symbiotec Pharmalab IPO Important Dates
| Particular | Dates |
|---|---|
| IPO Open Date | 24 Aug 2026 |
| IPO Close Date | 27 Aug 2026 |
| Basis of Allotment | 28 Aug 2026 |
| Refunds | - |
| Credit to Demat Account | - |
| IPO Listing Date | 01 Sept 2026 |
Note: The timeline for ಸಿಂಬಿಯೋಟೆಕ್ ಫಾರ್ಮಾಲ್ಯಾಬ್ IPO is tentative and subject to change.
Symbiotec Pharmalab Promoters and Shareholding Pattern
The promoters of Symbiotec Pharmalab are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP. Before the IPO, the promoter and promoter group collectively hold 2,16,33,968 equity shares, representing approximately 34.47% of the company's pre-IPO shareholding.
Other shareholders hold 4,00,47,528 equity shares, accounting for approximately 65.53% of the pre-IPO equity share capital. The company's total pre-IPO outstanding equity shares stand at 6,16,81,496.
Based on the provided holding pattern, the total number of outstanding equity shares is expected to increase to 6,32,02,757 shares after completion of the IPO.
Promoters of Symbiotec Pharmalab
- Anil Satwani
- Kashish Satwani
- Sushil Satwani
- Satwani Holdings LLP
| Particular | Pre IPO Shares | Pre IPO % Shares | Post IPO Shares | Post IPO % Shares |
|---|---|---|---|---|
| Promoter and Promoter Group | 2,16,33,968 | 34.47% | – | -% |
| Others* | 4,00,47,528 | 65.53% | – | -% |
| Total | 6,16,81,496 | 100% | 6,32,02,757 | 100% |
Symbiotec Pharmalab Objects of the Issue & Utilisation of Proceeds
To Be Updated Soon
Symbiotec Pharmalab About the IPO
To be updated soon
Symbiotec Pharmalab Company Financial Report
To Be Updated Soon
Symbiotec Pharmalab Company Valuation & Key Performance Indicators
To Be Updated Soon
Symbiotec Pharmalab Peer Group Comparison
To Be Updated Soon
Symbiotec Pharmalab Lead Managers & Merchant Bankers
- JM Financial Ltd.
- Avendus Capital Pvt. Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt. Ltd.
Symbiotec Pharmalab IPO FAQs
Symbiotec Pharmalab IPO opens for subscription on 23 August 2026 and closes on 26 August 2026.
The price band for Symbiotec Pharmalab IPO is set at ₹938.00 to ₹988.00 per share.
The minimum market lot size is 15 shares. A retail investor can apply for a minimum of 1 lot requiring an investment of 15 Shares (₹14,820).
The latest Grey Market Premium (GMP) for Symbiotec Pharmalab IPO is ₹185. GMP represents the unofficial premium at which shares trade prior to listing.
The basis of allotment for Symbiotec Pharmalab IPO is tentatively scheduled for 27 August 2026, and shares are expected to list on the stock exchanges on 31 August 2026.
The registrar details will be confirmed in the official prospectus.